US Dermatologists’ Lack of Success with Current Treatment Options in Vitiligo Paves the Way for Pipeline Advanced Systemic Agents to Disrupt the Market, According to Spherix Global Insights
- Friday, June 24, 2022, 7:13
- PR Newswire
- Add a comment
Dermatologists are most enthused about the potential utility of the JAK inhibitor class, including Incyte’s Opzelura, AbbVie’s Rinvoq, Pfizer’s ritlecitinib, and Incyte’s INCB54707 EXTON, Pa., June 24, 2022 /PRNewswire/ — Vitiligo is a disease that causes loss of skin color in patches…
About the Author
admin has written 21717 stories on this site.